Activation of ROS-driven genomic instability, mitochondrial depolarization, and p53-independent apoptotic cell death in human A431 epidermoid skin cancer cells by bioactive glass nanoparticles - Scorecard - MDSpire
Advertisement
Activation of ROS-driven genomic instability, mitochondrial depolarization, and p53-independent apoptotic cell death in human A431 epidermoid skin cancer cells by bioactive glass nanoparticles
Clinical Scorecard: Activation of ROS-driven genomic instability, mitochondrial depolarization, and p53-independent apoptotic cell death in human A431 epidermoid skin cancer cells by bioactive glass nanoparticles
At a Glance
Category
Detail
Condition
Cutaneous Squamous Cell Carcinoma (cSCC)
Key Mechanisms
Reactive oxygen species (ROS) generation, mitochondrial membrane disruption, genomic instability, and apoptosis induction.
Target Population
Patients with epidermoid skin cancer, particularly those with advanced or recurrent lesions.
Care Setting
Oncology and dermatology clinics, research laboratories.
Key Highlights
cSCC is the second most common non-melanoma skin cancer, with rising incidence due to UV exposure and immunosuppression.
Conventional treatments have limitations including toxicity and poor efficacy in advanced cases.
Bioactive glass nanoparticles (BGNPs) show promise as a novel therapeutic approach with selective cytotoxicity.
BGNPs induce cell death through ROS generation and mitochondrial dysfunction without chemotherapeutic agents.
This study provides the first evaluation of BGNPs in epidermoid carcinoma cells.
Guideline-Based Recommendations
Diagnosis
Clinical evaluation and histopathological examination for cSCC.
Management
Surgical excision for early-stage cSCC; consideration of BGNPs for advanced cases.
Monitoring & Follow-up
Regular follow-up for recurrence and metastasis in high-risk patients.
Risks
Potential for local invasion and metastasis in advanced cSCC.
Patient & Prescribing Data
Patients with epidermoid skin cancer, especially those unresponsive to conventional therapies.
BGNPs may offer a targeted approach with reduced systemic toxicity compared to traditional chemotherapy.
Clinical Best Practices
Consider integrating nanotechnology-based therapies in treatment plans for advanced cSCC.
Monitor for adverse effects and treatment efficacy in patients receiving BGNPs.
